BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 28170405)

  • 21. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.
    Agarwal A; Yadav AK; Kumar A; Gupta S; Panwala HK; Redhu N; Hariprasad S; Ranjan P; Arora A; Gupta A
    Indian J Gastroenterol; 2015 Mar; 34(2):117-26. PubMed ID: 25937484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma.
    Chen MY; Juengpanich S; Hu JH; Topatana W; Cao JS; Tong CH; Lin J; Cai XJ
    World J Gastroenterol; 2020 Mar; 26(10):1042-1055. PubMed ID: 32205995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS; Park MH; Jeon GS
    Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort.
    Yoon HM; Kim JH; Kim EJ; Gwon DI; Ko GY; Ko HK
    J Vasc Interv Radiol; 2013 Nov; 24(11):1639-46. PubMed ID: 23962438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
    Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma.
    Golfieri R; Mosconi C; Cappelli A; Giampalma E; Galaverni MC; Pettinato C; Renzulli M; Monari F; Angelelli B; Pini P; Terzi E; Ascanio S; Garzillo G; Piscaglia F; Bolondi L; Trevisani F
    Future Oncol; 2015; 11(23):3133-42. PubMed ID: 26467398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transarterial Chemoembolization Followed by Radiotherapy Versus Sandwich Treatment for Unresectable or Ablative Hepatocellular Carcinoma.
    Lin H; Wu H; Cong N; Liu B; Liu C; Han D
    Technol Cancer Res Treat; 2020; 19():1533033820983799. PubMed ID: 33357168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
    Adhoute X; Pénaranda G; Raoul JL; Bollon E; Pol B; Letreut YP; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Hardwigsen J; Lefolgoc G; Castellani P; Bronowicki JP; Bourlière M
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):706-715. PubMed ID: 28195873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
    Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
    Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization.
    Ray CE; Brown AC; Green TJ; Winston H; Curran C; Kreidler SM; Glueck DH; Rochon PJ
    AJR Am J Roentgenol; 2015 Feb; 204(2):440-7. PubMed ID: 25615768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TACE Combined with HIFU Versus Surgical Resection for Single Hepatocellular Carcinoma with Child-Pugh B Cirrhosis in Overall Survival and Progression-Free Survival: A Retrospective Study.
    Zhang Q; Wang Y; Zhang J; Zhang W; Gong J; Ma R
    Technol Cancer Res Treat; 2021; 20():15330338211060180. PubMed ID: 34855560
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases.
    Yoo JJ; Lee JH; Lee SH; Lee M; Lee DH; Cho Y; Lee YB; Yu SJ; Kim HC; Kim YJ; Yoon JH; Kim CY; Lee HS
    PLoS One; 2014; 9(11):e113926. PubMed ID: 25427152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study.
    Kim JK; Kim JW; Lee IJ; Joo SM; Lee KH; Cho ES; Yu JS; Jeon TJ; Kim Y; Lee JI; Lee KS
    Radiat Oncol; 2017 Aug; 12(1):133. PubMed ID: 28810886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.